Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. / Fosbøl, E L; Gislason, G H; Jacobsen, S; Folke, F; Hansen, M L; Schramm, T K; Sørensen, R; Rasmussen, J N; Andersen, S S; Abildstrom, S Z; Traerup, J; Poulsen, H E; Rasmussen, S; Køber, L; Torp-Pedersen, C.
In: Clinical Pharmacology and Therapeutics, Vol. 85, No. 2, 2008, p. 190-7.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study
AU - Fosbøl, E L
AU - Gislason, G H
AU - Jacobsen, S
AU - Folke, F
AU - Hansen, M L
AU - Schramm, T K
AU - Sørensen, R
AU - Rasmussen, J N
AU - Andersen, S S
AU - Abildstrom, S Z
AU - Traerup, J
AU - Poulsen, H E
AU - Rasmussen, S
AU - Køber, L
AU - Torp-Pedersen, C
N1 - Keywords: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Child; Cohort Studies; Cross-Over Studies; Death; Denmark; Female; Humans; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Risk Factors; Young Adult
PY - 2008
Y1 - 2008
N2 - Use of some nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with increased cardiovascular risk in several patient groups, but whether this excess risk exists in apparently healthy individuals has not been clarified. Using a historical cohort design, we estimated the risk of death and myocardial infarction associated with the use of NSAIDs. Participants in the study were selected from the Danish population and were defined as healthy according to a history of no hospital admissions and no concomitant selected pharmacotherapy. The source population consisted of 4,614,807 individuals, of whom 1,028,437 were included in the study after applying selection criteria. Compared to no NSAID use, hazard ratios (95% confidence limits) for death/myocardial infarction were 1.01 (0.96-1.07) for ibuprofen, 1.63 (1.52-1.76) for diclofenac, 0.97 (0.83-1.12) for naproxen, 2.13 (1.89-2.41) for rofecoxib, and 2.01 (1.78-2.27) for celecoxib. A dose-dependent increase in cardiovascular risk was seen for selective COX-2 inhibitors and diclofenac. Caution should be exercised in NSAID use in all individuals, and particularly high doses should be avoided if possible.
AB - Use of some nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with increased cardiovascular risk in several patient groups, but whether this excess risk exists in apparently healthy individuals has not been clarified. Using a historical cohort design, we estimated the risk of death and myocardial infarction associated with the use of NSAIDs. Participants in the study were selected from the Danish population and were defined as healthy according to a history of no hospital admissions and no concomitant selected pharmacotherapy. The source population consisted of 4,614,807 individuals, of whom 1,028,437 were included in the study after applying selection criteria. Compared to no NSAID use, hazard ratios (95% confidence limits) for death/myocardial infarction were 1.01 (0.96-1.07) for ibuprofen, 1.63 (1.52-1.76) for diclofenac, 0.97 (0.83-1.12) for naproxen, 2.13 (1.89-2.41) for rofecoxib, and 2.01 (1.78-2.27) for celecoxib. A dose-dependent increase in cardiovascular risk was seen for selective COX-2 inhibitors and diclofenac. Caution should be exercised in NSAID use in all individuals, and particularly high doses should be avoided if possible.
U2 - 10.1038/clpt.2008.204
DO - 10.1038/clpt.2008.204
M3 - Journal article
C2 - 18987620
VL - 85
SP - 190
EP - 197
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
SN - 0009-9236
IS - 2
ER -
ID: 17398685